Literature DB >> 27855276

Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.

Fabrice Usseglio1, Nathalie Beaufils2, Anne Calleja3, Sophie Raynaud3, Jean Gabert4.   

Abstract

Myeloproliferative neoplasms are clonal hematopoietic stem cell disorders characterized by aberrant proliferation and an increased tendency toward leukemic transformation. The genes JAK2, MPL, and CALR are frequently altered in these syndromes, and their mutations are often a strong argument for diagnosis. We analyzed the mutational profiles of these three genes in a cohort of 164 suspected myeloproliferative neoplasms. JAK2 V617F mutation was detected by real-time PCR, whereas high-resolution melting analysis followed by Sanger sequencing were used for searching for mutations in JAK2 exon 12, CALR, and MPL. JAK2 V617F mutation was associated with CALR (n = 4) and MPL (n = 4) mutations in 8 of 103 essential thrombocytosis patients. These cases were harboring a JAK2 V617F allelic burden of <4% and a significantly higher platelet count compared with JAK2 V617F (P < 0.001) and CALR (P = 0.001) single-mutation patients. The findings from this study support the possibility of coexisting mutations of the JAK2, CALR, and MPL genes in myeloproliferative neoplasms and suggest that CALR and MPL should be analyzed not only in JAK2-negative patients but also in low V617F mutation patients. Follow-up of these double-mutation cases will be important for determining whether this group of patients presents particular evolution or complications.
Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27855276     DOI: 10.1016/j.jmoldx.2016.08.006

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  6 in total

1.  Clinical acceleration of JAK2 p.V617F driven myeloproliferative disease due to a new uncommon homozygous MPL p.Y591D mutation.

Authors:  Jeremy Ong; Jane I Lin; Helen Mitchell; Susan Morgan; Andrew C Perkins
Journal:  Haematologica       Date:  2020-06-04       Impact factor: 9.941

2.  Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.

Authors:  Ken-Hong Lim; Caleb Gon-Shen Chen; Yu-Cheng Chang; Yi-Hao Chiang; Chen-Wei Kao; Wei-Ting Wang; Chiao-Yi Chang; Ling Huang; Ching-Sung Lin; Chun-Chia Cheng; Hung-I Cheng; Nai-Wen Su; Johnson Lin; Yi-Fang Chang; Ming-Chih Chang; Ruey-Kuen Hsieh; Huan-Chau Lin; Yuan-Yeh Kuo
Journal:  Oncotarget       Date:  2017-05-16

3.  A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.

Authors:  Dorota Link-Lenczowska; Niels Pallisgaard; Sabrina Cordua; Magdalena Zawada; Sylwia Czekalska; Dorota Krochmalczyk; Zuzanna Kanduła; Tomasz Sacha
Journal:  Ann Hematol       Date:  2018-07-28       Impact factor: 3.673

4.  A Rare Co-Occurrence of Triple Mutations in JAK2, CALR, and MPL in the Same Patient with Myelofibrosis.

Authors:  Sherine J Thomas; D P Dash
Journal:  Case Rep Hematol       Date:  2022-02-21

5.  Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms.

Authors:  Ka Shing Yow; Xin Liu; Chean Nee Chai; Moon Ley Tung; Benedict Yan; Dheepa Christopher; Kiat Hoe Ong; Melissa G Ooi
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01

Review 6.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.